nms-1286937
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2009 (NCT01014429)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serine/threonine-protein kinase PLK1INHIBITOR
PLK1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(N2CCN(C)CC2)cc1Nc1ncc2c(n1)-c1c(c(C(N)=O)nn1C)CC2- Mol. weight
- 448.53 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1094408 ↗
Also known as
- nms-1286937
- nms-1286937
- nms-1286937
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01014429 | Phase 1 | Nov 1, 2009 | Nerviano Medical Sciences, Scottsdale Healthcare |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nerviano Medical Sciences | For profit | 1 | 1 | 1 | 2009 |
| Scottsdale Healthcare | Academic/Hospital | 1 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1